56 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may … supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may also allow … basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used … with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase
8-K
EX-99.1
oh4jzc u73
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
brk76 o0ub8errh5zsd2
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
1d1o7gq2pi
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
6reuvc6r
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
bmr9v
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
e6y2jshu
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
khxug82aa8wcfps4rkdb
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
ahbs2k
15 Apr 21
Other Events
12:00am
8-K
EX-1.1
ghkdrmd6br61s mv3gc
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
lep1blv mvu
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
3mhs3yo8qjjtg
22 Oct 19
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
mkycp8
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm
424B3
ljficz7 7k22bdaw
12 Apr 19
Prospectus supplement
4:41pm